Jupiter Neurosciences, Inc. Common Stock (NASDAQ:JUNS) — Market Cap & Net Worth
Market Cap & Net Worth: Jupiter Neurosciences, Inc. Common Stock (JUNS)
Jupiter Neurosciences, Inc. Common Stock (NASDAQ:JUNS) has a market capitalization of $13.43 Million ($13.43 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26145 globally and #5229 in its home market, demonstrating a 1.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jupiter Neurosciences, Inc. Common Stock's stock price $0.39 by its total outstanding shares 34426355 (34.43 Million). Analyse how efficiently does Jupiter Neurosciences, Inc. Common Stock generate cash to see how efficiently the company converts income to cash.
Jupiter Neurosciences, Inc. Common Stock Market Cap History: 2024 to 2026
Jupiter Neurosciences, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $368.36 Million to $13.43 Million (0.00% CAGR).
Index Memberships
Jupiter Neurosciences, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #749 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2464 of 3165 |
Weight: Jupiter Neurosciences, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jupiter Neurosciences, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jupiter Neurosciences, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of JUNS by Market Capitalization
Companies near Jupiter Neurosciences, Inc. Common Stock in the global market cap rankings as of May 4, 2026.
Key companies related to Jupiter Neurosciences, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Jupiter Neurosciences, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Jupiter Neurosciences, Inc. Common Stock's market cap moved from $368.36 Million to $ 13.43 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $13.43 Million | -61.76% |
| 2025 | $35.11 Million | -90.47% |
| 2024 | $368.36 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Jupiter Neurosciences, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.43 Million USD |
| MoneyControl | $13.43 Million USD |
| MarketWatch | $13.43 Million USD |
| marketcap.company | $13.43 Million USD |
| Reuters | $13.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phas… Read more